Corporate Disclosures Highlight Stark Divergence Between Cash-Rich Incumbents and Strained Niche TechGlobal Report·5 hours agoWU-0.83%MRVI+3.08%
The Fringes of the Value Chain: From Hard Infrastructure to Financial UnbundlingGlobal Report·7 hours agoPCG+0.25%VG-2.92%
Maravai LifeSciences (NASDAQ:MRVI) Sees Large Volume Increase - Still a Buy?Market Beat·Aug 20 at 10:21 AMMRVI+3.08%
Small-Cap Volatility Signals: The Rise of Single-Stock Leveraged Tactical ToolsGlobal Report·Aug 20 at 05:17 AMKUST-1.52%OPENZ+11.95%
Maravai LifeSciences (NASDAQ:MRVI) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPSMarket Beat·Aug 8 at 02:41 PMMRVI+3.08%
Maravai LifeSciences posts investor presentation on mRNA, gene editing, cell and gene therapy tools platformPUBT·Aug 7 at 09:29 AMMRVI+3.08%
MRVI: Q2 revenue up 9% with margin gains, strong TriLink growth, and prudent guidance maintainedQuartr·Aug 6 at 06:10 PMMRVI+3.08%
Maravai Q2 FY26 net loss narrows to $21.6 million; revenue rises 8.5% to $51.4 millionPUBT·Aug 6 at 03:05 PMMRVI+3.08%
Biotech Stocks At 52-Week Highs - MEDP And NVCR Rise With Positive Q2 Reports, ETON, MRVI, ADVBrttnews·Jul 24 at 05:31 AMETON-0.95%ADVB+6.98%
Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026 | MRVI Stock NewsStockTitan·Jul 22 at 07:02 AMMRVI+3.08%
